Evidence map›Paper›PMID 38035495›Full record

ArticleMultiple sclerosis and related disorders2024

A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.

Shishir Dahal, Yohance M Allette, Kerry Naunton, Daniel M Harrison

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. The CNS Meninges and the Synovial Joint: Parallel Immunological Structures in Autoimmune Disease.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  3. Review
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shishir DahalDepartment of Neurology, University of Maryland School of Medicine, 110 S Paca St, 3rd Floor, Baltimore, MD 21201, United States.
Yohance M AlletteDepartment of Neurology, University of Maryland School of Medicine, 110 S Paca St, 3rd Floor, Baltimore, MD 21201, United States; Baltimore VA Medical Center, Baltimore, MD, United States.
Kerry NauntonDepartment of Neurology, University of Maryland School of Medicine, 110 S Paca St, 3rd Floor, Baltimore, MD 21201, United States.
Daniel M HarrisonDepartment of Neurology, University of Maryland School of Medicine, 110 S Paca St, 3rd Floor, Baltimore, MD 21201, United States; Baltimore VA Medical Center, Baltimore, MD, United States. Electronic address: dharrison@som.umaryland.edu.
University of Maryland, Baltimore · US

Funding

In vivo assessment of meningeal inflammation and its clinical impact in multiple sclerosis by 7 Tesla MRIR01NS104403 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI HARRISON, DANIEL M · 2018 to 2022
$3.1M
NINDS NIH HHS R01 NS104403
6 · The paper itself

Abstract

backgroundAutopsy data suggests that meningeal inflammation in multiple sclerosis (MS) is driven by CD20+ B-cells. Ocrelizumab is an anti-CD20 monoclonal antibody, and thus could potentially ameliorate meningeal inflammation in MS. Leptomeningeal enhancement (LME) on MRI is suggested as a surrogate biomarker of meningeal inflammation in MS, and thus may be a way of monitoring for this treatment effect.

objectivesTo determine if ocrelizumab impacts meningeal enhancement (ME) on 7T MRI in MS.

methodsTwenty-two patients with MS started on ocrelizumab by their treating physician were enrolled into this single-center, open-label, prospective trial. Participants underwent 7T MRI of the brain prior to first infusion, with screening for the presence of LME. Fourteen patients (48 ± 11 years; 11 women) had LME on the baseline scan and were invited to return for an additional 7T MRI after 1 year of treatment. Fourteen MS patients (49 ± 10 years; 11 women) on non-CD20 treatment from a separate observational cohort of annual 7T MRIs were used for comparison - matched for LME at baseline, age, and sex. Post-contrast FLAIR and subtraction images were reviewed for LME and paravascular and dural enhancement (PDE).

resultsAll subjects in the ocrelizumab and comparison groups had LME and PDE on their baseline scan. At the beginning of the study the mean number of foci of LME and PDE in the study group were 2.3 ± 1.7 and 6.6 ± 3.9 respectively. Mean LME and PDE count for the comparison group were 1.7 ± 1.5 and 7.8 ± 5.5. Mean volume of LME in the study group was 50.5 mm

conclusionIn this small pilot trial, ocrelizumab did not significantly reduce the number or volume of foci of LME or PDE in MS patients.

Indexed as

Antibodies, Monoclonal, HumanizedMultiple SclerosisFemaleHumansInflammationPilot ProjectsProspective StudiesAntibodies, Monoclonal, HumanizedocrelizumabMagnetic resonance imagingMeningeal enhancementMeningesMultiple sclerosisOcrelizumabPilot trial

Identifiers

PMID38035495
PMCPMC10843730
OpenAlexW4388996570

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.